6,110 results on '"Benigni, A"'
Search Results
102. Optimal delocalization for generalized Wigner matrices
- Author
-
Benigni, L. and Lopatto, P.
- Published
- 2022
- Full Text
- View/download PDF
103. C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19
- Author
-
Aiello, Sistiana, Gastoldi, Sara, Galbusera, Miriam, Ruggenenti, Piero, Portalupi, Valentina, Rota, Stefano, Rubis, Nadia, Liguori, Lucia, Conti, Sara, Tironi, Matteo, Gamba, Sara, Santarsiero, Donata, Benigni, Ariela, Remuzzi, Giuseppe, and Noris, Marina
- Published
- 2022
- Full Text
- View/download PDF
104. Evaluating confidence in toxicity assessments based on experimental data and in silico predictions
- Author
-
Johnson, Candice, Anger, Lennart T., Benigni, Romualdo, Bower, David, Bringezu, Frank, Crofton, Kevin M., Cronin, Mark T.D., Cross, Kevin P., Dettwiler, Magdalena, Frericks, Markus, Melnikov, Fjodor, Miller, Scott, Roberts, David W., Suarez-Rodrigez, Diana, Roncaglioni, Alessandra, Lo Piparo, Elena, Tice, Raymond R., Zwickl, Craig, and Myatt, Glenn J.
- Published
- 2022
- Full Text
- View/download PDF
105. Hausdorff Dimension of the Record Set of a Fractional Brownian Motion
- Author
-
Benigni, Lucas, Cosco, Clément, Shapira, Assaf, and Wiese, Kay Jörg
- Subjects
Mathematics - Probability - Abstract
We prove that the Hausdorff dimension of the record set of a fractional Brownian motion with Hurst parameter $H$ equals $H$.
- Published
- 2017
- Full Text
- View/download PDF
106. The physical constraints on a new LoBAL QSO at z=4.82
- Author
-
Yi, Weimin, Green, Richard, Bai, Jin-Ming, Wang, Tinggui, Grier, Catherine J., Trump, Jonathan R., Brandt, William N., Zuo, Wenwen, Yang, Jinyi, Wang, Feige, Yang, Chenwei, Wu, Xue-Bing, Zhou, Hongyan, Fan, Xiaohui, Jiang, Linhua, Yang, Qian, Varricatt, Watson, Kerr, Tom, Milne, Peter, Benigni, Sam, Wang, Jian-Guo, Zhang, Jujia, Wang, Fang, Wang, Chuan-Jun, Xin, Yu-Xin, Fan, Yu-Feng, Chang, Liang, Zhang, Xiliang, and Lun, Bao-Li
- Subjects
Astrophysics - Astrophysics of Galaxies - Abstract
Very few low-ionization broad absorption line (LoBAL) QSOs have been found at high redshifts to date. One high-redshift LoBAL QSO, J0122+1216, was recently discovered at the Lijiang 2.4-m Telescope with an initial redshift determination of 4.76. Aiming to investigate its physical properties, we carried out follow-up observations in the optical and near-IR spectroscopy. Near-IR spectra from UKIRT and P200 confirms that it is a LoBAL, with a new redshift determination of $4.82\pm0.01$ based on the \mgii~ emission-line. The new \mgii~ redshift determination reveals strong blueshifts and asymmetry of the high-ionization emission lines. We estimated a black hole mass of $\sim 2.3\times 10^9 M_\odot$ and Eddington ratio of $\sim 1.0$ according to the empirical \mgii-based single-epoch relation and bolometric correction factor. It is possible that strong outflows are the result of an extreme quasar environment driven by the high Eddington ratio. A lower limit on the outflowing kinetic power ($>0.9\% L_{Edd}$) was derived from both emission and absorption lines, indicating these outflows play a significant role in the feedback process to regulate the growth of its black hole as well as host galaxy evolution., Comment: 12 pages, 10 figures. Accepted for publication in The Astrophysical Journal
- Published
- 2017
- Full Text
- View/download PDF
107. Flavouring Group Evaluation 80, Revision 2 (FGE.80Rev2): Consideration of alicyclic, alicyclic‐fused and aromatic‐fused ring lactones evaluated by the JECFA (61st and 82nd meetings) structurally related to an aromatic lactone evaluated in FGE.27
- Author
-
Castle, Laurence, Andreassen, Monica, Aquilina, Gabriele, Bastos, Maria, Boon, Polly, Fallico, Biagio, Fitzgerald, Reginald, Frutos Fernandez, Maria Jose, Grasl‐Kraupp, Bettina, Gundert‐Remy, Ursula, Gürtler, Rainer, Houdeau, Eric, Kurek, Marcin, Louro, Henriqueta, Morales, Patricia, Passamonti, Sabina, Benigni, Romualdo, Degen, Gisela, Engel, Karl‐Heinz, and Fowler, Paul
- Subjects
FOOD additives ,FOOD consumption ,GENETIC toxicology ,LACTONES ,METABOLISM - Abstract
The EFSA Panel on Food Additives and Flavourings was requested to evaluate 14 flavouring substances assigned to the Flavouring Group Evaluation 80 (FGE.80), using the Procedure as outlined in the Commission Regulation (EC) No 1565/2000. Thirteen substances have already been considered in FGE.80 and its revision and in FGE.96 [FL‐no: 10.005, 10.024, 10.025, 10.050, 10.061, 10.069, 10.070, 10.072, 10.169, 13.009, 13.012, 13.161 and 16.055]. The remaining flavouring substance 3a,4,5,7a‐tetrahydro‐3,6‐dimethylbenzofuran‐2(3H)‐one [FL‐no: 10.057] has been cleared with respect to genotoxicity in FGE.217Rev3 and it is considered in this revision 2 of FGE.80. The substance [FL‐no: 10.057] was evaluated through a stepwise approach that integrates information on the structure–activity relationships, intake from current uses, threshold of toxicological concern (TTC) and available data on metabolism and toxicity. The Panel concluded that [FL‐no: 10.057] does not give rise to safety concerns at its levels of dietary intake, when estimated on the basis of the 'Maximised Survey‐derived Daily Intake' (MSDI) approach. Besides the safety assessment of the flavouring substance, the specifications for the material of commerce have also been considered and the information provided was complete for [FL‐no: 10.057]. However, for the flavouring substance [FL‐no: 10.057] in the present revision and for eight substances evaluated in previous revisions, the 'modified Theoretical Added Maximum Daily Intakes' (mTAMDIs) values are above the TTC for their structural class (III). For four substances previously evaluated in FGE.80Rev1 and in FGE.96, use levels are still needed to calculate the mTAMDI estimates. Therefore, in total for 13 flavouring substances, data on uses and use levels should be provided to finalise their safety evaluations. For [FL‐no: 10.050, 10.069 and 13.161], information on the composition of stereoisomeric mixtures is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
108. Neural-Network-based State Estimation: the effect of Pseudo- measurements.
- Author
-
Andrea Bragantini, Davide Baroli, Andres Felipe Posada-Moreno, and Andrea Benigni
- Published
- 2021
- Full Text
- View/download PDF
109. A Hardware-in-the-Loop Co-simulation of Multi-modal Energy System for Control Validation.
- Author
-
Diran Liu, Dominik Hering, Daniele Carta, André Xhonneux, Dirk Müller 0005, and Andrea Benigni
- Published
- 2021
- Full Text
- View/download PDF
110. Performance Evaluation of a Missing Data Recovery Approach Based on Compressive Sensing.
- Author
-
Daniele Carta and Andrea Benigni
- Published
- 2021
- Full Text
- View/download PDF
111. The unintended consequences of the pandemic on non-pandemic research activities
- Author
-
Walker, James, Brewster, Chris, Fontinha, Rita, Haak-Saheem, Washika, Benigni, Stefano, Lamperti, Fabio, and Ribaudo, Dalila
- Published
- 2022
- Full Text
- View/download PDF
112. Patient-Reported Outcomes and Return to Intended Oncologic Therapy After Colorectal Enhanced Recovery Pathway: The iCral3 Prospective Study
- Author
-
Catarci, Marco, Ruffo, Giacomo, Viola, Massimo Giuseppe, Ficari, Ferdinando, Delrio, Paolo, Pirozzi, Felice, Borghi, Felice, De Luca, Raffaele, Patriti, Alberto, Garulli, Gianluca, Siquini, Walter, D’Ugo, Stefano, Scabini, Stefano, Caricato, Marco, Pignata, Giusto, Liverani, Andrea, Campagnacci, Roberto, Marini, Pierluigi, Elmore, Ugo, Corcione, Francesco, Santoro, Roberto, Carlini, Massimo, Giuliani, Antonio, Sorrentino, Mario, Ferrari, Giovanni, Baldazzi, Gianandrea, Di Leo, Alberto, Verzelli, Augusto, Sica, Giuseppe, Rausei, Stefano, Cavaliere, Davide, Baiocchi, Gian Luca, Milone, Marco, Ciaccio, Giovanni, Tebala, Giovanni Domenico, Scatizzi, Marco, Boni, Luigi, Mancini, Stefano, Guerrieri, Mario, Persiani, Roberto, Lucchi, Andrea, Parini, Dario, Spinelli, Antonino, Genna, Michele, Bottino, Vincenzo, Coratti, Andrea, Scala, Dario, Muratore, Andrea, Pavanello, Maurizio, Rivolta, Umberto, Piccoli, Micaela, Talarico, Carlo, Carrara, Alessandro, Guadagni, Stefano, Totis, Mauro, Roviello, Franco, Anastasi, Alessandro, Guercioni, Gianluca, Maria Ettorre, Giuseppe, Montuori, Mauro, Mariani, Pierpaolo, de Manzini, Nicolò, Donini, Annibale, Armellino, Mariano Fortunato, Taglietti, Lucio, Anania, Gabriele, Di Cosmo, Mariantonietta, Feo, Carlo Vittorio, Millo, Paolo, Pedrazzani, Corrado, Guerriero, Silvio, Costanzi, Andrea, Vettoretto, Nereo, Marchesi, Federico, Basti, Massimo, Longo, Graziano, Cicetti, Moreno, Ciano, Paolo, Benedetti, Michele, Montemurro, Leonardo Antonio, Mattei, Maria Sole, Belloni, Elena, Bertocchi, Elisa, Masini, Gaia, Altamura, Amedeo, Rubichi, Francesco, Giudici, Francesco, Cianchi, Fabio, Baldini, Gabriele, Pace, Ugo, Bucci, Andrea Fares, Sciuto, Antonio, Cianflocca, Desirée, Migliore, Marco, Simone, Michele, Ricci, Marcella Lodovica, Monari, Francesco, Cardinali, Alessandro, Sartelli, Massimo, Spampinato, Marcello, Aprile, Alessandra, Soriero, Domenico, Capolupo, Gabriella Teresa, Andreuccetti, Jacopo, Canfora, Ilaria, Scarinci, Andrea, Maurizi, Angela, Attinà, Grazia Maria, Maggi, Giulia, Bracale, Umberto, Peltrini, Roberto, Amodio, Pietro, Spoletini, Domenico, Marcellinaro, Rosa, Del Vecchio, Giovanni, Stefanoni, Massimo, Magistro, Carmelo, Cassini, Diletta, Crepaz, Lorenzo, Budassi, Andrea, Sensi, Bruno, Tenconi, Silvia, Solaini, Leonardo, Ercolani, Giorgio, Molfino, Sarah, De Palma, Giovanni Domenico, Locurto, Paolo, Di Cintio, Antonio, Pandolfini, Lorenzo, Falsetto, Alessandro, Cassinotti, Elisa, Sagnotta, Andrea, Ortenzi, Monica, Biondi, Alberto, Martorelli, Giacomo, De Luca, Maurizio, Carrano, Francesco, Maroli, Annalisa, Fior, Francesca, Ferronetti, Antonio, Giuliani, Giuseppe, Benigni, Roberto, Marino, Graziella, Marsanic, Patrizia, Pipitone Federico, Nicoletta Sveva, Di Marco, Carlo, Bertoglio, Camillo Leonardo, Pecchini, Francesca, Greco, Vincenzo, Motter, Michele, Tirone, Giuseppe, Clementi, Marco, Tamini, Nicolò, Piagnerelli, Riccardo, Canonico, Giuseppe, Cicconi, Simone, Colasanti, Marco, Pinotti, Enrico, Carminati, Roberta, Osenda, Edoardo, Graziosi, Luigina, De Martino, Ciro, Ioia, Giovanna, Birindelli, Arianna, Chiozza, Matteo, Zigiotto, Daniele, Pindozzi, Fioralba, Grivon, Manuela, Conti, Cristian, Organetti, Lorenzo, Monteleone, Michela, Botteri, Emanuele, Dalmonte, Giorgio, Frazzini, Diletta, Santoni, Simone, La Gioia, Gabriele, and Giannarelli, Diana
- Published
- 2023
- Full Text
- View/download PDF
113. On Modeling Depths of Power Electronic Circuits for Real-Time Simulation – A Comparative Analysis for Power Systems
- Author
-
Giovanni De Carne, Georg Lauss, Mazheruddin H. Syed, Antonello Monti, Andrea Benigni, Shahab Karrari, Panos Kotsampopoulos, and Md. Omar Faruque
- Subjects
Real time simulation ,AC-DC power converters ,power systems modeling ,power electronics modeling ,Distribution or transmission of electric power ,TK3001-3521 ,Production of electric energy or power. Powerplants. Central stations ,TK1001-1841 - Abstract
Investigations of the dynamic behaviour of power electronic components integrated into electric networks require suitable and established simulation methodologies. Real-time simulation represents a frequently applied methodology for analyzing the steady-state and transient behavior of electric power systems. This work introduces a guideline on how to model power electronics converters in digital real time simulators, taking into account the trade-off between model accuracy and the required computation time. Based on this concept, possible execution approaches with respect to the usage of central processing unit and field-programmable gate array components are highlighted. Simulation test scenario, such as primary frequency regulation and low voltage ride through, have been performed and accuracy indices are discussed for each implemented real-time model and each test scenario, respectively. Finally, a run-time analysis of presented real-time setups is given and real-time simulation results are compared. This manuscript demonstrates important differences in real-time simulation modelling, providing useful guidelines for the decision making of power engineers.
- Published
- 2022
- Full Text
- View/download PDF
114. Sirt3 deficiency promotes endothelial dysfunction and aggravates renal injury.
- Author
-
Anna Pezzotta, Luca Perico, Daniela Corna, Marina Morigi, Giuseppe Remuzzi, Ariela Benigni, and Barbara Imberti
- Subjects
Medicine ,Science - Abstract
Sirtuin 3 (SIRT3), the main deacetylase of mitochondria, modulates the acetylation levels of substrates governing metabolism and oxidative stress. In the kidney, we showed that SIRT3 affects the proper functioning of high energy-demanding cells, such as tubular cells and podocytes. Less is known about the role of SIRT3 in regulating endothelial cell function and its impact on the progression of kidney disease. Here, we found that whole body Sirt3-deficient mice exhibited reduced renal capillary density, reflecting endothelial dysfunction, and VEGFA expression compared to wild-type mice. This was paralleled by activation of hypoxia signaling, upregulation of HIF-1α and Angiopietin-2, and oxidative stress increase. These alterations did not result in kidney disease. However, when Sirt3-deficient mice were exposed to the nephrotoxic stimulus Adriamycin (ADR) they developed aggravated endothelial rarefaction, altered VEGFA signaling, and higher oxidative stress compared to wild-type mice receiving ADR. As a result, ADR-treated Sirt3-deficient mice experienced a more severe injury with exacerbated albuminuria, podocyte loss and fibrotic lesions. These data suggest that SIRT3 is a crucial regulator of renal vascular homeostasis and its dysregulation is a predisposing factor for kidney disease. By extension, our findings indicate SIRT3 as a pharmacologic target in progressive renal disease whose treatments are still imperfect.
- Published
- 2023
- Full Text
- View/download PDF
115. CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome
- Author
-
Rossella Piras, Elisabetta Valoti, Marta Alberti, Elena Bresin, Caterina Mele, Matteo Breno, Lucia Liguori, Roberta Donadelli, Miriam Rigoldi, Ariela Benigni, Giuseppe Remuzzi, and Marina Noris
- Subjects
atypical hemolytic uremic syndrome (aHUS) ,eculizumab ,factor H (FH) ,factor H-related proteins (FHRs) ,complement ,copy number variations (CNVs) ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionAtypical hemolytic uremic syndrome (aHUS) is a rare disease that manifests with microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure, and is associated with dysregulation of the alternative complement pathway. The chromosomal region including CFH and CFHR1-5 is rich in repeated sequences, favoring genomic rearrangements that have been reported in several patients with aHUS. However, there are limited data on the prevalence of uncommon CFH-CFHR genomic rearrangements in aHUS and their impact on disease onset and outcomes.MethodsIn this study, we report the results of CFH-CFHR Copy Number Variation (CNV) analysis and the characterization of resulting structural variants (SVs) in a large cohort of patients, including 258 patients with primary aHUS and 92 with secondary forms.ResultsWe found uncommon SVs in 8% of patients with primary aHUS: 70% carried rearrangements involving CFH alone or CFH and CFHR (group A; n=14), while 30% exhibited rearrangements including only CFHRs (group B; n=6). In group A, 6 patients presented CFH::CFHR1 hybrid genes, 7 patients carried duplications in the CFH-CFHR region that resulted either in the substitution of the last CFHR1 exon(s) with those of CFH (CFHR1::CFH reverse hybrid gene) or in an internal CFH duplication. In group A, the large majority of aHUS acute episodes not treated with eculizumab (12/13) resulted in chronic ESRD; in contrast, anti-complement therapy induced remission in 4/4 acute episodes. aHUS relapse occurred in 6/7 grafts without eculizumab prophylaxis and in 0/3 grafts with eculizumab prophylaxis. In group B, 5 subjects had the CFHR31-5::CFHR410 hybrid gene and one had 4 copies of CFHR1 and CFHR4. Compared with group A, patients in group B exhibited a higher prevalence of additional complement abnormalities and earlier disease onset. However, 4/6 patients in this group underwent complete remission without eculizumab treatment. In secondary forms we identified uncommon SVs in 2 out of 92 patients: the CFHR31-5::CFHR410 hybrid and a new internal duplication of CFH.DiscussionIn conclusion, these data highlight that uncommon CFH-CFHR SVs are frequent in primary aHUS and quite rare in secondary forms. Notably, genomic rearrangements involving the CFH are associated with a poor prognosis but carriers respond to anti-complement therapy.
- Published
- 2023
- Full Text
- View/download PDF
116. Binominal constructions with metaphorical quantifiers in Russian: 'vsplesk ėmocij i volna pozitiva'
- Author
-
Valentina Benigni
- Subjects
Binominal Constructions ,Metaphorical Quantifiers ,Arrangement Classifiers ,Support Nouns ,Russian Language ,History of Eastern Europe ,DJK1-77 ,Slavic languages. Baltic languages. Albanian languages ,PG1-9665 - Abstract
The paper provides a usage-based description of left-headed Russian binominals of the type [N1[metaphorical quantifier]N2GEN] (e.g. vsplesk ėmocij ‘a surge of emotions’, volna pozitiva ‘a wave of positivity’), where N1 is used metaphorically and tends to ‘grammaticalize’ into a quantifier and/or intensifier, denoting a large quantity or a sudden increase of N2. The analysis presents two case studies based on complex upward/forward-oriented movements: vsplesk ‘surge’ and volna ‘wave’. The study, set in the framework of cognitive linguistics, adopts a usage-based approach in order to identify the classes of N2-collocates for the two quantifiers/intensifiers and determine which semantic (intensity, arrangement, shape), actional (inchoativity, iterativity and multiactionality) and pragmatic features (i.e., connotation, evaluation, speaker’s attitude towards increasing processes and large quantities) are mapped from N1 onto N2.
- Published
- 2023
- Full Text
- View/download PDF
117. Explant of one graft due to technical complications in dual kidney transplants: analysis of the long-term function of the remaining kidney
- Author
-
Collini, Andrea, Miccoli, Simone, Piccioni, Stefania, Benigni, Roberto, Ruggieri, Giuliana, and Carmellini, Mario
- Published
- 2021
- Full Text
- View/download PDF
118. Post-translational modifications by SIRT3 de-2-hydroxyisobutyrylase activity regulate glycolysis and enable nephrogenesis
- Author
-
Luca Perico, Marina Morigi, Anna Pezzotta, Daniela Corna, Valerio Brizi, Sara Conti, Cristina Zanchi, Fabio Sangalli, Piera Trionfini, Sara Buttò, Christodoulos Xinaris, Susanna Tomasoni, Carlamaria Zoja, Giuseppe Remuzzi, Ariela Benigni, and Barbara Imberti
- Subjects
Medicine ,Science - Abstract
Abstract Abnormal kidney development leads to lower nephron number, predisposing to renal diseases in adulthood. In embryonic kidneys, nephron endowment is dictated by the availability of nephron progenitors, whose self-renewal and differentiation require a relatively repressed chromatin state. More recently, NAD+-dependent deacetylase sirtuins (SIRTs) have emerged as possible regulators that link epigenetic processes to the metabolism. Here, we discovered a novel role for the NAD+-dependent deacylase SIRT3 in kidney development. In the embryonic kidney, SIRT3 was highly expressed only as a short isoform, with nuclear and extra-nuclear localisation. The nuclear SIRT3 did not act as deacetylase but exerted de-2-hydroxyisobutyrylase activity on lysine residues of histone proteins. Extra-nuclear SIRT3 regulated lysine 2-hydroxyisobutyrylation (Khib) levels of phosphofructokinase (PFK) and Sirt3 deficiency increased PFK Khib levels, inducing a glycolysis boost. This altered Khib landscape in Sirt3 −/− metanephroi was associated with decreased nephron progenitors, impaired nephrogenesis and a reduced number of nephrons. These data describe an unprecedented role of SIRT3 in controlling early renal development through the regulation of epigenetics and metabolic processes.
- Published
- 2021
- Full Text
- View/download PDF
119. Scientific Guidance on the data required for the risk assessment of flavourings to be used in or on foods
- Author
-
EFSA Panel on Food Additives and Flavourings (FAF), Maged Younes, Gabriele Aquilina, Laurence Castle, Gisela Degen, Paul J Fowler, Maria Jose Frutos Fernandez, Peter Fürst, Ursula Gundert‐Remy, Rainer Gürtler, Trine Husøy, Melania Manco, Wim Mennes, Peter Moldeus, Sabina Passamonti, Romina Shah, Ine Waalkens‐Berendsen, Detlef Wölfle, Matthew Wright, Romualdo Benigni, Claudia Bolognesi, Polly Boon, Kevin Chipman, Joop De Knecht, Karin Nørby, Davide Arcella, Stefania Barmaz, Maria Carfì, Marcello Laganaro, Carla Martino, Alexandra Tard, Giorgia Vianello, and Karl‐Heinz Engel
- Subjects
Food flavourings ,flavouring substances ,flavouring preparations ,thermal process flavourings ,flavour precursors ,other flavourings ,Nutrition. Foods and food supply ,TX341-641 ,Chemical technology ,TP1-1185 - Abstract
Abstract Following a request from the European Commission, EFSA developed a new scientific guidance to assist applicants in the preparation of applications for the authorisation of flavourings to be used in or on foods. This guidance applies to applications for a new authorisation as well as for a modification of an existing authorisation of a food flavouring, submitted under Regulation (EC) No 1331/2008. It defines the scientific data required for the evaluation of those food flavourings for which an evaluation and approval is required according to Article 9 of Regulation (EC) No 1334/2008. This applies to flavouring substances, flavouring preparations, thermal process flavourings, flavour precursors, other flavourings and source materials, as defined in Article 3 of Regulation (EC) No 1334/2008. Information to be provided in all applications relates to: (a) the characterisation of the food flavouring, including the description of its identity, manufacturing process, chemical composition, specifications, stability and reaction and fate in foods; (b) the proposed uses and use levels and the assessment of the dietary exposure and (c) the safety data, including information on the genotoxic potential of the food flavouring, toxicological data other than genotoxicity and information on the safety for the environment. For the toxicological studies, a tiered approach is applied, for which the testing requirements, key issues and triggers are described. Applicants should generate the data requested in each section to support the safety assessment of the food flavouring. Based on the submitted data, EFSA will assess the safety of the food flavouring and conclude whether or not it presents risks to human health and to the environment, if applicable, under the proposed conditions of use.
- Published
- 2022
- Full Text
- View/download PDF
120. Twitter Discourse in the Southeaster Conference
- Author
-
Benigni, Vincent L., primary and Porter, Lance V., additional
- Published
- 2022
- Full Text
- View/download PDF
121. WCN24-2379 NATURAL HISTORY OF PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: HOW DOES 1-YEAR PROTEINURIA CORRELATE WITH LONG-TERM RENAL OUTCOME?
- Author
-
Marasa, Maddalena, primary, Nanchen, Giliane, additional, Marasa', Maddalena, additional, Breno, Matteo, additional, Martinatto, Carolina, additional, Rigoldi, Miriam, additional, Noris, Marina, additional, Bresin, Elena, additional, Gamba, Sara, additional, Bottanelli, Laura, additional, Imanifard, Zahra, additional, Piras, Rossella, additional, Donadelli, Roberta, additional, Benigni, Ariela, additional, Remuzzi, Giuseppe, additional, and Daina, Erica, additional
- Published
- 2024
- Full Text
- View/download PDF
122. The Pan - COVID - AGICT Study. The impact of COVID-19 pandemic on surgically treated pancreatic cancer patients. A multicentric Italian study.
- Author
-
Dorma, Maria Pia Federica, primary, Giuliani, Giuseppe, additional, Guerra, Francesco, additional, Santelli, Francesco, additional, Esposito, Alessandro, additional, De Pastena, Matteo, additional, Turri, Giulia, additional, Pedrazzani, Corrado, additional, Kauffmann, Emanuele Federico, additional, Boggi, Ugo, additional, Solaini, Leonardo, additional, Ercolani, Giorgio, additional, Mastrangelo, Laura, additional, Jovine, Elio, additional, Di Franco, Gregorio, additional, Morelli, Luca, additional, Mazzola, Michele, additional, Ferrari, Giovanni, additional, Langella, Serena, additional, Ferrero, Alessandro, additional, La Mendola, Roberta, additional, Abu Hilal, Mohamnad, additional, Depalma, Norma, additional, D’Ugo, Stefano, additional, Spampinato, Marcello Giuseppe, additional, Frisini, Marco, additional, Brolese, Alberto, additional, Palaia, Raffaele, additional, Belli, Andrea, additional, Cillara, Nicola, additional, Deserra, Antonello, additional, Cannavera, Alessandro, additional, Sagnotta, Andrea, additional, Mancini, Stefano, additional, Pinotti, Enrico, additional, Montuori, Mauro, additional, Coppola, Alessandro, additional, Di Benedetto, Fabrizio, additional, Coratti, Andrea, additional, Cova, Chiara, additional, Bianchi, Beatrice, additional, Nobile, Sara, additional, Maruccio, Martina, additional, Faustini, Federico, additional, Hilal, Mohamnad Abu, additional, Pecora, Irene, additional, Messinese, Simona, additional, Salvischiani, Lucia, additional, Esposito, Sofia, additional, Ferraro, Luca, additional, Rega, Daniela, additional, Delrio, Paolo, additional, La Raja, Carlotta, additional, Spinelli, Antonino, additional, Massaron, Simonetta, additional, De Nardi, Paola, additional, Deidda, Simona, additional, Restivo, Angelo, additional, Marano, Alessandra, additional, Borghi, Felice, additional, Piccoli, Micaela, additional, Cozzani, Federico, additional, Del Rio, Paolo, additional, Marcellinaro, Rosa, additional, Carlini, Massimo, additional, De Rosa, Raffaele, additional, Scabini, Stefano, additional, Maiello, Fabio, additional, Polastri, Roberto, additional, Zese, Monica, additional, Parini, Dario, additional, Casaril, Andrea, additional, Moretto, Gianluigi, additional, De Leo, Antonio, additional, Catarci, Marco, additional, Trapani, Renza, additional, Zonta, Sandro, additional, Marsanic, Patrizia, additional, Muratore, Andrea, additional, Caputo, Damiano, additional, Andreuccetti, Jacopo, additional, Pignata, Giusto, additional, Mariani, Lorenzo, additional, Ceccarelli, Graziano, additional, Giuseppe, Rocco, additional, Bolzon, Stefano, additional, Grasso, Mariateresa, additional, Testa, Silvio, additional, Germani, Paola, additional, de Manzini, Nicolò, additional, Coletta, Diego, additional, De Franco, Lorenzo, additional, Benigni, Roberto, additional, Tribuzi, Angela, additional, Marra, Ubaldo, additional, Di Marino, Michele, additional, Zorcolo, Luigi, additional, Lisi, Giorgio, additional, Allisiardi, Fabrizio, additional, Grieco, Michele, additional, Righetti, Carolina, additional, Grassia, Michele, additional, Lucchi, Andrea, additional, Bagaglini, Giulia, additional, Sica, Giuseppe S., additional, Manara, Michele, additional, Turati, Luca, additional, Macone, Lorenzo, additional, Carminati, Roberta, additional, Mariani, Pierpaolo, additional, Rizzo, Gianluca, additional, Coco, Claudio, additional, Pennella, Francesca Pennetti, additional, Rondelli, Fabio, additional, Romano, Lucia, additional, Giuliani, Antonio, additional, Albino, Vittorio, additional, Leongito, Maddalena, additional, David, Giulia, additional, Misitano, Pasquale, additional, Pasulo, Silvia, additional, Baiocchi, Gian Luca, additional, Baldari, Ludovica, additional, Cassinotti, Elisa, additional, Boni, Luigi, additional, Capolupo, Gabriella Teresa, additional, Caricato, Marco, additional, Bombardini, Cristina, additional, Anania, Gabriele, additional, Dibra, Rigers, additional, Martines, Gennaro, additional, Oliva, Renato, additional, Carati, Maria Vittoria, additional, Grazi, Gian Luca, additional, Marchegiani, Francesco, additional, Spolverato, Gaya, additional, Celotto, Francesco, additional, Pucciarelli, Salvatore, additional, La Torre, Filippo, additional, Iannone, Immacolata, additional, Krizzuk, Dimitri, additional, Sammartino, Francesco, additional, Catalano, Giorgia, additional, Strignano, Paolo, additional, Romagnoli, Renato, additional, Piccione, Domenico, additional, Nardo, Bruno, additional, Reddavid, Rossella, additional, Degiuli, Maurizio, additional, Gerosa, Martino, additional, Maggioni, Dario, additional, Zuolo, Michele, additional, Rigamonti, Marco, additional, Ghazouani, Omar, additional, Galleano, Raffaele, additional, Percivale, Andrea, additional, Tirloni, Luca, additional, Moraldi, Luca, additional, Fabbri, Nicolò, additional, Feo, Carlo Vittorio, additional, Colombo, Samuele, additional, Merlini, Ilenia, additional, Di Saverio, Salomone, additional, Barbato, Giuseppe, additional, Coratti, Francesco, additional, Formisano, Giampaolo, additional, Bianchi, Paolo Pietro, additional, and Bengala, Carmelo, additional
- Published
- 2024
- Full Text
- View/download PDF
123. Efficacy of GalNAc C3 siRNAs in factor H-deficient mice with C3 glomerulopathy
- Author
-
Zanchi, Cristina, primary, Locatelli, Monica, additional, Cerullo, Domenico, additional, Aumiller, Verena, additional, Corna, Daniela, additional, Rottoli, Daniela, additional, Schubert, Steffen, additional, Noris, Marina, additional, Tomasoni, Susanna, additional, Remuzzi, Giuseppe, additional, Zoja, Carlamaria, additional, and Benigni, Ariela, additional
- Published
- 2024
- Full Text
- View/download PDF
124. Interface pressures and stiffnesses of different bandages studied on a Hiraï leg
- Author
-
Benigni, J-P, primary, UHL, JF, additional, Balet, F, additional, and Filori, P, additional
- Published
- 2024
- Full Text
- View/download PDF
125. Indications, contraindications, side effects, general assessment, and outlook for the future: An International Compression Club survey
- Author
-
Giovanni, Mosti, primary, Angrit, Namislo, additional, Jean Patrick, Benigni, additional, Eduardo, Da Matta, additional, Hugo, Partsch, additional, Martin, Schmitz, additional, and Martin, Abel, additional
- Published
- 2024
- Full Text
- View/download PDF
126. In silico approaches in carcinogenicity hazard assessment: Current status and future needs
- Author
-
Tice, Raymond R., Bassan, Arianna, Amberg, Alexander, Anger, Lennart T., Beal, Marc A., Bellion, Phillip, Benigni, Romualdo, Birmingham, Jeffrey, Brigo, Alessandro, Bringezu, Frank, Ceriani, Lidia, Crooks, Ian, Cross, Kevin, Elespuru, Rosalie, Faulkner, David M., Fortin, Marie C., Fowler, Paul, Frericks, Markus, Gerets, Helga H.J., Jahnke, Gloria D., Jones, David R., Kruhlak, Naomi L., Piparo, Elena Lo, Lopez-Belmonte, Juan, Luniwal, Amarjit, Luu, Alice, Madia, Federica, Manganelli, Serena, Manickam, Balasubramanian, Mestres, Jordi, Mihalchik-Burhans, Amy L., Neilson, Louise, Pandiri, Arun, Pavan, Manuela, Rider, Cynthia V., Rooney, John P., Trejo-Martin, Alejandra, Watanabe-Sailor, Karen H., White, Angela T., Woolley, David, and Myatt, Glenn J.
- Published
- 2021
- Full Text
- View/download PDF
127. In silico assessment of genotoxicity. Combinations of sensitive structural alerts minimize false negative predictions for all genotoxicity endpoints and can single out chemicals for which experimentation can be avoided
- Author
-
Benigni, Romualdo
- Published
- 2021
- Full Text
- View/download PDF
128. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
- Author
-
Lempp, Florian A., Soriaga, Leah B., Montiel-Ruiz, Martin, Benigni, Fabio, Noack, Julia, Park, Young-Jun, and Bianchi, Siro
- Subjects
Angiotensin converting enzyme -- Physiological aspects -- Health aspects ,Lectins -- Physiological aspects -- Health aspects ,Environmental issues ,Science and technology ,Zoology and wildlife conservation - Abstract
SARS-CoV-2 infection--which involves both cell attachment and membrane fusion--relies on the angiotensin-converting enzyme 2 (ACE2) receptor, which is paradoxically found at low levels in the respiratory tract.sup.1-3, suggesting that there may be additional mechanisms facilitating infection. Here we show that C-type lectin receptors, DC-SIGN, L-SIGN and the sialic acid-binding immunoglobulin-like lectin 1 (SIGLEC1) function as attachment receptors by enhancing ACE2-mediated infection and modulating the neutralizing activity of different classes of spike-specific antibodies. Antibodies to the amino-terminal domain or to the conserved site at the base of the receptor-binding domain, while poorly neutralizing infection of ACE2-overexpressing cells, effectively block lectin-facilitated infection. Conversely, antibodies to the receptor binding motif, while potently neutralizing infection of ACE2-overexpressing cells, poorly neutralize infection of cells expressing DC-SIGN or L-SIGN and trigger fusogenic rearrangement of the spike, promoting cell-to-cell fusion. Collectively, these findings identify a lectin-dependent pathway that enhances ACE2-dependent infection by SARS-CoV-2 and reveal distinct mechanisms of neutralization by different classes of spike-specific antibodies. C-type lectins and SIGLEC1 function as attachment receptors for SARS-CoV-2 and enhance ACE2-mediated infection., Author(s): Florian A. Lempp [sup.1] , Leah B. Soriaga [sup.1] , Martin Montiel-Ruiz [sup.1] , Fabio Benigni [sup.2] , Julia Noack [sup.1] , Young-Jun Park [sup.3] , Siro Bianchi [sup.2] [...]
- Published
- 2021
- Full Text
- View/download PDF
129. First Tests on a Prototype Device for the Active Control of Whole-Body Vibrations on Agricultural Tractors
- Author
-
Pochi, Daniele, Fornaciari, Laura, Grilli, Renato, Betto, Monica, Benigni, Stefano, Fanigliulo, Roberto, di Prisco, Marco, Series Editor, Chen, Sheng-Hong, Series Editor, Vayas, Ioannis, Series Editor, Kumar Shukla, Sanjay, Series Editor, Sharma, Anuj, Series Editor, Kumar, Nagesh, Series Editor, Wang, Chien Ming, Series Editor, Coppola, Antonio, editor, Di Renzo, Giovanni Carlo, editor, Altieri, Giuseppe, editor, and D'Antonio, Paola, editor
- Published
- 2020
- Full Text
- View/download PDF
130. Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence
- Author
-
Cazaubon M, Benigni JP, Steinbruch M, Jabbour V, and Gouhier-Kodas C
- Subjects
chronic venous disorders ,venoactive drugs ,flavonoids ,randomized clinical trials ,literature review. ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Michèle Cazaubon,1 Jean-Patrick Benigni,2 Marcio Steinbruch,3 Violaine Jabbour,4 Christelle Gouhier-Kodas4 1Private Vascular Specialist, Paris, France; 2Pedagogical Support Office, Faculty of Medicine Pitié-Salpétrière, Sorbonne University, Paris, France; 3Hospital Albert Einstein, São Paulo, Brazil; 4Laboratoire Innotech International, Arcueil, FranceCorrespondence: Christelle Gouhier-Kodas Email christelle.gouhier-kodas@innothera.comAbstract: Flavonoids are oral venoactive drugs frequently prescribed to relieve the symptoms of chronic venous disorders (CVD). Among venoactive drugs, diosmin is a naturally occurring flavonoid glycoside that can be isolated from various plant sources; it can also be obtained after conversion of hesperidin extracted from citrus rinds. Micronized purified flavonoid fraction (MPFF) is a preparation that contains mainly diosmin and a small fraction of hesperidin. We performed a state-of-the-art literature review to collect and analyze well-conducted randomized clinical studies comparing diosmin – also called non-micronized or hemisynthetic diosmin – 600 mg a day and MPFF, 1000 mg a day. Three clinical studies met the criteria and were included for this literature review. These clinical studies showed a significant decrease of CVD symptom intensity (up to approximately 50%) and global patient satisfaction after one-to-six-month treatment with diosmin or MPFF, without statistical differences between these two forms of diosmin. Both treatments were well tolerated with few mild adverse drug reactions reported. Overall, based on this literature review, there is no clinical benefit to increase the dose of diosmin beyond 600 mg per day, to use the micronized form, or to add hesperidin, since clinical efficacy on venous symptomatology is achieved with 600 mg per day of pure non-micronized diosmin. This challenges the status of diosmin – 600 mg a day – in guidelines for the management of CVD, which is currently categorized 2C (weak recommendations for use and poor quality of evidence), while the most widely used and assessed preparation MPFF is rated 1B (strong recommendation for use and moderate quality of evidence).Keywords: chronic venous disorders, venoactive drugs, flavonoids, randomized clinical trials, literature review
- Published
- 2021
131. Broad sarbecovirus neutralization by a human monoclonal antibody
- Author
-
Tortorici, M. Alejandra, Czudnochowski, Nadine, Starr, Tyler N., Marzi, Roberta, Walls, Alexandra C., Zatta, Fabrizia, Bowen, John E., Jaconi, Stefano, Di Iulio, Julia, Wang, Zhaoqian, De Marco, Anna, Zepeda, Samantha K., Pinto, Dora, Liu, Zhuoming, Beltramello, Martina, Bartha, Istvan, Housley, Michael P., Lempp, Florian A., Rosen, Laura E., Dellota, Jr, Exequiel, Kaiser, Hannah, Montiel-Ruiz, Martin, Zhou, Jiayi, Addetia, Amin, Guarino, Barbara, Culap, Katja, Sprugasci, Nicole, Saliba, Christian, Vetti, Eneida, Giacchetto-Sasselli, Isabella, Fregni, Chiara Silacci, Abdelnabi, Rana, Foo, Shi-Yan Caroline, Havenar-Daughton, Colin, Schmid, Michael A., Benigni, Fabio, Cameroni, Elisabetta, Neyts, Johan, Telenti, Amalio, Virgin, Herbert W., Whelan, Sean P. J., Snell, Gyorgy, Bloom, Jesse D., Corti, Davide, Veesler, David, and Pizzuto, Matteo Samuele
- Published
- 2021
- Full Text
- View/download PDF
132. Comparative Evaluation of Characterization Methods for Powders Used in Additive Manufacturing
- Author
-
Mitterlehner, Marco, Danninger, Herbert, Gierl-Mayer, Christian, Gschiel, Harald, Martinez, Carlos, Tomisser, Manuel, Schatz, Michael, Senck, Sascha, Auer, Jaqueline, and Benigni, Caterina
- Published
- 2021
- Full Text
- View/download PDF
133. Editorial: Women in renal pharmacology: 2021
- Author
-
Ariela Benigni and Susanna Tomasoni
- Subjects
sex ,chronic kidney disease ,diabetic nephropathy ,angiotensin II receptor blocker ,receptor tyrosine kinases ,Therapeutics. Pharmacology ,RM1-950 - Published
- 2022
- Full Text
- View/download PDF
134. Scientific opinion on Flavouring group evaluation 216 revision 2 (FGE.216Rev2): consideration of the genotoxicity potential of α,β‐unsaturated 2‐phenyl‐2‐alkenals from subgroup 3.3 of FGE.19
- Author
-
EFSA Panel on Food Additives and Flavourings (FAF), Maged Younes, Gabriele Aquilina, Laurence Castle, Gisela Degen, Karl‐Heinz Engel, Paul J. Fowler, Maria Jose Frutos Fernandez, Peter Fürst, Ursula Gundert‐Remy, Rainer Gürtler, Trine Husøy, Melania Manco, Peter Moldeus, Sabina Passamonti, Romina Shah, Ine Waalkens‐Berendsen, Matthew Wright, Romualdo Benigni, Claudia Bolognesi, Kevin Chipman, Eugenia Cordelli, Karin Nørby, Camilla Svendsen, Maria Carfì, Carla Martino, and Wim Mennes
- Subjects
FGE.216 ,α,β‐unsaturated 2‐phenyl‐2‐alkenals ,flavouring substances ,safety evaluation ,subgroup 3.3 ,FGE.19 ,Nutrition. Foods and food supply ,TX341-641 ,Chemical technology ,TP1-1185 - Abstract
Abstract The EFSA Panel on Food Additives and Flavourings (FAF) was requested to evaluate the genotoxic potential of five flavouring substances from subgroup 3.3 of FGE.19, in the Flavouring Group Evaluation 216 (FGE.216). In FGE.216 and in FGE.216Rev1, the CEF Panel requested additional genotoxicity data on 2‐phenylcrotonaldehyde [FL‐no: 05.062], the representative for these five substances. New experimental data on [FL‐no: 05.062] were provided and are evaluated in the present revision of FGE.216 (FGE.216Rev2). Based on the new data, the Panel concluded that, for all the five substances, the concerns for gene mutations and clastogenicity are ruled out by the negative results observed in an in vivo gene mutation assay and in an in vivo comet assay, respectively. In vitro, [FL‐no: 05.062] induced micronuclei through an aneugenic mode of action. The available in vivo micronucleus studies were inconclusive and cannot be used to rule out potential aneugenicity of [FL‐no: 05.062] in vivo. Therefore, the Panel compared the lowest concentration resulting in aneugenicity in vitro with the use levels reported for this substance. Based on this comparison, the Panel concluded that the use of the flavouring substance [FL‐no: 05.062] at the reported use levels in several food categories would raise a concern for aneugenicity. Based on structural similarity, for the remaining four substances in this FGE [FL‐no: 05.099, 05.100, 05.175 and 05.222], an aneugenic potential may also be anticipated. For these four substances, individual data are needed to establish whether they have aneugenic potential. Accordingly, it is currently not appropriate to assess any of these five substances through the Procedure for the evaluation of flavouring substances.
- Published
- 2022
- Full Text
- View/download PDF
135. Experimental investigation and thermodynamic evaluation of the CsNO3-LiNO3-NaNO3 ternary system
- Author
-
Kouassi, Edouard Koffi, Manouan, Max Wedjers, Zoro, Eulogne, Boa, David, Benigni, Pierre, Zamali, Hmida, Rogez, Jacques, and Hellali, Dalila
- Published
- 2021
- Full Text
- View/download PDF
136. Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine
- Author
-
Piera Trionfini, Elena Romano, Marco Varinelli, Lorena Longaretti, Paola Rizzo, Roberta Giampietro, Annalina Caroli, Sistiana Aiello, Marta Todeschini, Federica Casiraghi, Giuseppe Remuzzi, Ariela Benigni, and Susanna Tomasoni
- Subjects
hypoimmunogenic iPSC ,cell therapy ,regenerative medicine ,endothelial cells ,hepatocytes ,hepatic stellate cells ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Induced pluripotent stem cells (iPSC) have huge potential as cell therapy for various diseases, given their potential for unlimited self-renewal and capability to differentiate into a wide range of cell types. Although autologous iPSCs represents the ideal source for patient-tailored regenerative medicine, the high costs of the extensive and time-consuming production process and the impracticability for treating acute conditions hinder their use for broad applications. An allogeneic iPSC-based strategy may overcome these issues, but it carries the risk of triggering an immune response. So far, several approaches based on genome-editing techniques to silence human leukocyte antigen class I (HLA-I) or II (HLA-II) expression have been explored to overcome the immune rejection of allogeneic iPSCs. In this study, we employed the CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9) system to delete the β2-Microglobulin (B2M) and the Class II Major Histocompatibility Complex Transactivator (CIITA) genes, essential for the correct surface expression of HLA-I and HLA-II proteins. The resulting hypoimmunogenic iPSC line has a normal karyotype, expresses the pluripotency stem cell markers, and is capable of differentiating into the three embryonic germ layers. Furthermore, we showed that it specifically retains the ability to differentiate towards different liver cells, such as endothelial-like cells, hepatocyte-like cells, and hepatic stellate-like cells. Our results indicate that hypoimmunogenic iPSCs could give a new cost-effective and off-the-shelf opportunity for cell therapy in liver diseases.
- Published
- 2023
- Full Text
- View/download PDF
137. Assessment of Energy, Dynamic and Economic Balance of Chipping Operation in Poplar Medium Rotation Coppice (MRC) Plantations
- Author
-
Walter Stefanoni, Roberto Fanigliulo, Daniele Pochi, Laura Fornaciari, Renato Grilli, Stefano Benigni, Francesco Latterini, and Giulio Sperandio
- Subjects
comminution ,work productivity ,sustainable forest operations ,bioenergy ,wood chips ,Plant ecology ,QK900-989 - Abstract
Exploiting renewable energy sources is one of the main strategies defined by the EU to overcome dependence on foreign markets for energy supply. Wood fuel sourced from the agroforestry sector can contribute significantly to achieving the goal, though its economic and environmental sustainability is intimately dependent on proper harvesting and chipping operations. In the present article, both economic and environmental aspects of Medium Rotation Coppice (MRC) were investigated regarding chipping. A small-scale chipper and tractor were equipped with real-time sensors to monitor time, t (s); fuel consumption, F (cm3); PTO torque, M (daNm); PTO speed, s (min−1); and stem diameter, D (mm) during the comminution of 61 poplar plants (gathered in 5 classes according to trunk diameter) grown in MRC system. More than 29,000 records were taken and analyzed. Predictive models for working time, working productivity, CO2 emission, energy consumption, fuel consumption and costs were also produced. Higher diametric classes exhibited lower fuel consumption, less CO2 emission and less energy demand during chipping. Time and operating costs were statistically different among classes, with minimum values of 0.22 (SD ± 0.02) h·Mg−1 and 12.07 (SD ± 0.93) €·Mg−1 in class 5 and maximum values of 0.64 (SD ± 0.09) h·Mg−1 and 35.34 (SD ± 4.88) €·Mg−1 in class 1, respectively. Fuel consumption ranges from 3.04 (SD ± 0.88) L·Mg−1 in class 5 to 7.32 (SD ± 1.46) L·Mg−1 in class 1. The lowest CO2 emission of 8.03 (SD ± 2.32) kg·Mg−1 was found class 5. However, the total cost of coppice production did not exceed large-scale MRC production due to the lower purchase price of the machinery involved. Eventually, predictive models showed high reliability as estimating tools for important variables, such as working time, working productivity, CO2 emissions, energy consumption, fuel consumption and costs.
- Published
- 2023
- Full Text
- View/download PDF
138. Sport Case Chapter: A Crisis of Cool
- Author
-
Benigni, Vince, primary and Porter, Lance, additional
- Published
- 2022
- Full Text
- View/download PDF
139. Chapter 12. Morphopragmatics of rhyming and imitative co-compounds in Russian
- Author
-
Alexandrova, Anna, primary and Benigni, Valentina, additional
- Published
- 2021
- Full Text
- View/download PDF
140. Amnion epithelial cells are an effective source of factor H and prevent kidney complement deposition in factor H-deficient mice
- Author
-
Federica Casiraghi, Pamela Yossenaidy Rodriguez Ordonez, Nadia Azzollini, Marta Todeschini, Daniela Rottoli, Roberta Donadelli, Roberto Gramignoli, Ariela Benigni, Marina Noris, and Giuseppe Remuzzi
- Subjects
Human amnion epithelial cells ,Complement factor H ,Complement alternative pathway ,Renal glomeruli ,Complement deposition ,Medicine (General) ,R5-920 ,Biochemistry ,QD415-436 - Abstract
Abstract Complement factor H (FH) is the main plasma regulator of the alternative pathway of complement. Genetic and acquired abnormalities in FH cause uncontrolled complement activation amplifying, with the consequent accumulation of complement components on the renal glomeruli. This leads to conditions such as C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS). There is no effective therapy for these diseases. Half of the patients progress to end-stage renal disease and the condition recurs frequently in transplanted kidneys. Combined liver/kidney transplantation is a valid option for these patients, but the risks of the procedure and donor organ shortages hamper its clinical application. Therefore, there is an urgent need for alternative strategies for providing a normal FH supply. Human amnion epithelial cells (hAEC) have stem cell characteristics, including the capability to differentiate into hepatocyte-like cells in vivo. Here, we administered hAEC into the livers of newborn Cfh −/− mice, which spontaneously developed glomerular complement deposition and renal lesions resembling human C3G. hAEC engrafted at low levels in the livers of Cfh −/− mice and produced sufficient human FH to prevent complement activation and glomerular C3 and C9 deposition. However, long-term engraftment was not achieved, and eventually hAEC elicited a humoral immune response in immunocompetent Cfh −/− mice. hAEC cell therapy could be a valuable therapeutic option for patients undergoing kidney transplantation in whom post-transplant immunosuppression may protect allogeneic hAEC from rejection, while allogeneic cells provide normal FH to prevent disease recurrence.
- Published
- 2021
- Full Text
- View/download PDF
141. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital
- Author
-
Abbonizio, Maria Alessandra, Abdeddaim, Amina, Agostini, Elisabetta, Agrati, Chiara, Albarello, Fabrizio, Amadei, Gioia, Amendola, Alessandra, Antinori, Andrea, Antonica, Maria Assunta, Antonini, Mario, Bartoli, Tommaso Ascoli, Baldini, Francesco, Barbaro, Raffaella, Bartolini, Barbara, Bellagamba, Rita, Benigni, Martina, Bevilacqua, Nazario, Biava, Gianluigi, Bibas, Michele, Bordi, Licia, Bordoni, Veronica, Boumis, Evangelo, Branca, Marta, Buonomo, Rosanna, Busso, Donatella, Camici, Marta, Campioni, Paolo, Canichella, Flaminia, Capobianchi, Maria Rosaria, Capone, Alessandro, Caporale, Cinzia, Caraffa, Emanuela, Caravella, Ilaria, Carletti, Fabrizio, Castilletti, Concetta, Cataldo, Adriana, Cerilli, Stefano, Cerva, Carlotta, Chiappini, Roberta, Chinello, Pierangelo, Cianfarani, Maria Assunta, Ciaralli, Carmine, Cimaglia, Claudia, Cinicola, Nicola, Ciotti, Veronica, Cicalini, Stefania, Colavita, Francesca, Corpolongo, Angela, Cristofaro, Massimo, Curiale, Salvatore, D’Abramo, Alessandra, Dantimi, Cristina, De Angelis, Alessia, De Angelis, Giada, De Palo, Maria Grazia, De Zottis, Federico, Di Bari, Virginia, Di Lorenzo, Rachele, Di Stefano, Federica, D’Offizi, Gianpiero, Donno, Davide, Evangelista, Francesca, Faraglia, Francesca, Farina, Anna, Ferraro, Federica, Fiorentini, Lorena, Frustaci, Andrea, Fusetti, Matteo, Galati, Vincenzo, Gagliardini, Roberta, Gallì, Paola, Garotto, Gabriele, Gaviano, Ilaria, Tekle, Saba Gebremeskel, Giancola, Maria Letizia, Giansante, Filippo, Giombini, Emanuela, Granata, Guido, Greci, Maria Cristina, Grilli, Elisabetta, Grisetti, Susanna, Gualano, Gina, Iacomi, Fabio, Iaconi, Marta, Iannicelli, Giuseppina, Inversi, Carlo, Ippolito, Giuseppe, Lalle, Eleonora, Lamanna, Maria Elena, Lanini, Simone, Lapa, Daniele, Lepore, Luciana, Libertone, Raffaella, Lionetti, Raffaella, Liuzzi, Giuseppina, Loiacono, Laura, Lucia, Andrea, Lufrani, Franco, Macchione, Manuela, Maffongelli, Gaetano, Marani, Alessandra, Marchioni, Luisa, Mariano, Andrea, Marini, Maria Cristina, Maritti, Micaela, Mastrobattista, Annelisa, Mastrorosa, Ilaria, Matusali, Giulia, Mazzotta, Valentina, Mencarini, Paola, Meschi, Silvia, Messina, Francesco, Micarelli, Sibiana, Mogavero, Giulia, Mondi, Annalisa, Montalbano, Marzia, Montaldo, Chiara, Mosti, Silvia, Murachelli, Silvia, Musso, Maria, Nardi, Michela, Navarra, Assunta, Nicastri, Emanuele, Nocioni, Martina, Noto, Pasquale, Noto, Roberto, Oliva, Alessandra, Onnis, Ilaria, Ottou, Sandrine, Palazzolo, Claudia, Pallini, Emanuele, Palmieri, Fabrizio, Palombi, Giulio, Pareo, Carlo, Passeri, Virgilio, Pelliccioni, Federico, Penna, Giovanna, Petrecchia, Antonella, Petrone, Ada, Petrosillo, Nicola, Pianura, Elisa, Pinnetti, Carmela, Pisciotta, Maria, Piselli, Pierluca, Pittalis, Silvia, Pontarelli, Agostina, Proietti, Costanza, Puro, Vincenzo, Ramazzini, Paolo Migliorisi, Rianda, Alessia, Rinonapoli, Gabriele, Rosati, Silvia, Rubino, Dorotea, Rueca, Martina, Ruggeri, Alberto, Sacchi, Alessandra, Sampaolesi, Alessandro, Sanasi, Francesco, Santagata, Carmen, Scarabello, Alessandra, Scarcia, Silvana, Schininà, Vincenzo, Scognamiglio, Paola, Scorzolini, Laura, Stazi, Giulia, Strano, Giacomo, Taglietti, Fabrizio, Taibi, Chiara, Taloni, Giorgia, Nardi, Tetaj, Tonnarini, Roberto, Topino, Simone, Tozzi, Martina, Vaia, Francesco, Vairo, Francesco, Valli, Maria Beatrice, Vergori, Alessandra, Vincenzi, Laura, Visco-Comandini, Ubaldo, Vita, Serena, Vittozzi, Pietro, Zaccarelli, Mauro, Zanetti, Antonella, Zito, Sara, Lorenzini, Patrizia, Di Gennaro, Francesco, and Girardi, Enrico
- Published
- 2021
- Full Text
- View/download PDF
142. CALPHAD modeling of the glass transition for a pure substance, coupling thermodynamics and relaxation kinetics
- Author
-
Benigni, P.
- Published
- 2021
- Full Text
- View/download PDF
143. New insights into the Cs-Mo-O system: Experimental studies of the Cs2MoO4-MoO3 pseudo-binary system
- Author
-
Smith, A.L., Vlieland, J., Pignié, M.-C., Abbink, M., Mikaelian, G., and Benigni, P.
- Published
- 2021
- Full Text
- View/download PDF
144. Navigating Concepts in the Human Mind Unravels the Latent Geometry of Its Semantic Space.
- Author
-
Barbara Benigni, Monica Dallabona, Elena Bravi, Stefano Merler, and Manlio De Domenico
- Published
- 2021
- Full Text
- View/download PDF
145. Scientific opinion on flavouring group evaluation 415 (FGE.415): (E)‐3‐benzo[1,3]dioxol‐5‐yl‐N,N‐diphenyl‐2‐propenamide
- Author
-
EFSA Panel on Food Additives and Flavourings (FAF), Maged Younes, Gabriele Aquilina, Laurence Castle, Gisela Degen, Karl‐Heinz Engel, Paul J Fowler, Maria Jose Frutos Fernandez, Peter Fürst, Ursula Gundert‐Remy, Rainer Gürtler, Trine Husøy, Melania Manco, Peter Moldeus, Sabina Passamonti, Romina Shah, Ine Waalkens‐Berendsen, Matthew Wright, Romualdo Benigni, Claudia Bolognesi, Kevin Chipman, Eugenia Cordelli, Karin Nørby, Camilla Svendsen, Maria Carfí, Giorgia Vianello, and Wim Mennes
- Subjects
(E)‐3‐benzo[1,3]dioxol‐5‐yl‐N,N‐diphenyl‐2‐propenamide ,FGE.415 ,flavouring ,FL‐no: 16.135 ,Nutrition. Foods and food supply ,TX341-641 ,Chemical technology ,TP1-1185 - Abstract
Abstract The EFSA Panel on Food Additives and Flavourings (FAF) was requested to evaluate the safety of the substance (E)‐3‐benzo[1,3]dioxol‐5‐yl‐N,N‐diphenyl‐2‐propenamide [FL‐no: 16.135] as a new flavouring substance, in accordance with Regulation (EC) No 1331/2008. The substance has not been reported to occur naturally and it is chemically synthesised. It is intended to be used as a flavouring substance in specific categories of food, but not intended to be used in beverages. The chronic dietary exposure to [FL‐no: 16.135] estimated using the added portions exposure technique (APET), is calculated to be 780 μg/person per day for a 60‐kg adult and 480 μg/person per day for a 15‐kg 3‐year‐old child. [FL‐no: 16.135] did not show genotoxic effects in bacterial mutagenicity and mammalian cell micronucleus assays in vitro. Developmental toxicity was not observed in a study in rats at the dose levels up to 1,000 mg/kg body weight (bw) per day. The Panel derived a BMDL of 101 mg/kg bw per day from a 90‐day toxicity study. Based on this BMDL, adequate margins of exposure of 7,800 and 3,200 could be calculated for adults and children, respectively. The Panel concluded that there is no safety concern for [FL‐no: 16.135], when used as a flavouring substance at the estimated level of dietary exposure calculated using the APET approach, based on the intended uses and use levels as specified in Appendix B. The Panel further concluded that the combined exposure to [FL‐no: 16.135] from its use as a food flavouring substance and from its presence in toothpaste is also not of safety concern.
- Published
- 2022
- Full Text
- View/download PDF
146. Safety and efficacy of a feed additive consisting of Sunset Yellow FCF for cats and dogs, ornamental fish, grain‐eating ornamental birds and small rodents (Sensient Colours Europe GmbH)
- Author
-
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Vasileios Bampidis, Giovanna Azimonti, Maria de Lourdes Bastos, Henrik Christensen, Birgit Dusemund, Mojca Fašmon Durjava, Maryline Kouba, Marta López‐Alonso, Secundino López Puente, Francesca Marcon, Baltasar Mayo, Alena Pechová, Mariana Petkova, Fernando Ramos, Yolanda Sanz, Roberto Edoardo Villa, Ruud Woutersen, Kettil Stevensen, Romualdo Benigni, Rosella Brozzi, Jaume Galobart, Orsolya Holczknecht, Matteo Lorenzo Innocenti, Fabiola Pizzo, and Maria Vittoria Vettori
- Subjects
Sunset Yellow FCF ,colourant ,pets ,safety ,efficacy ,Nutrition. Foods and food supply ,TX341-641 ,Chemical technology ,TP1-1185 - Abstract
Abstract Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Sunset Yellow FCF for cats, dogs, ornamental fish, grain‐eating ornamental birds and small rodents when used as an additive that adds or restores colour in feedingstuffs. Sunset Yellow FCF is considered safe for the target species at the following concentrations in complete feed: 165 mg/kg for cats, 198 mg/kg for dogs, 733 mg/kg for ornamental fish, 24 mg/kg for grain‐eating ornamental birds and 750 mg/kg for small rodents. In the absence of adequate information, the FEEDAP Panel cannot conclude neither on the eyes and skin irritation potential of Sunset yellow FCF, nor on its skin sensitisation potential. Exposure by inhalation is considered to be unlikely. The FEEDAP Panel cannot conclude on the efficacy of the additive.
- Published
- 2022
- Full Text
- View/download PDF
147. Scientific opinion on Prosmoke BW 01
- Author
-
EFSA Panel on Food Additives and Flavourings (FAF), Maged Younes, Gabriele Aquilina, Laurence Castle, Karl‐Heinz Engel, Paul J Fowler, Maria Jose Frutos Fernandez, Peter Fürst, Ursula Gundert‐Remy, Rainer Gürtler, Trine Husøy, Melania Manco, Peter Moldeus, Sabina Passamonti, Romina Shah, Ine Waalkens‐Berendsen, Detlef Wölfle, Matthew Wright, Romualdo Benigni, Claudia Bolognesi, Eugenia Cordelli, Kevin Chipman, Gisela Degen, Karin Nørby, Camilla Svendsen, Maria Carfì, Carla Martino, Alexandra Tard, Giorgia Vianello, and Wim Mennes
- Subjects
Prosmoke BW 01 ,smoke flavouring primary product ,furan‐2(5H)‐one ,genotoxicity ,Nutrition. Foods and food supply ,TX341-641 ,Chemical technology ,TP1-1185 - Abstract
Abstract The EFSA Panel on Food Additives and Flavourings (FAF) was requested to evaluate the safety of Prosmoke BW 01 as a new smoke flavouring primary product, in accordance with Regulation (EC) No 2065/2003. Prosmoke BW01 is produced by pyrolysis of beechwood (Fagus sylvatica L.) sawdust. Its water content is estimated at 56 wt%, the total identified volatile fraction accounts for 28 wt% of the primary product, corresponding to 64% of the solvent‐free mass, while the unidentified fraction amounts to 16 wt% of the primary product. Analytical data provided for three batches demonstrated that their batch‐to‐batch‐variability was sufficiently low. However, for the batch used for the toxicological studies, there were substantial deviations in the concentration of nearly all the constituents compared to the other three batches. The dietary exposure of Prosmoke BW 01 was estimated to be between 6.2 and 9.2 mg/kg body weight (bw) per day, respectively, using SMK‐EPIC and SMK‐TAMDI. Using the FAIM tool, the 95th percentile exposure estimates ranged from 3.2 mg/kg bw per day for the elderly to 17.9 mg/kg bw per day for children. The Panel noted that furan‐2(5H)‐one is present in all batches of the primary product at an average concentration of 0.88 wt%. This substance was evaluated by the FAF Panel as genotoxic in vivo after oral exposure. The Panel considered that the (geno)toxicity studies available on the whole mixture were not adequate to support the safety assessment, due to limitations in these studies and because they were performed with a batch which may not be representative for the material of commerce. Considering that the exposure estimates for furan‐2(5H)‐one are above the TTC value of 0.0025 μg/kg bw per day (or 0.15 μg/person per day) for DNA‐reactive mutagens and/or carcinogens, the Panel concluded that Prosmoke BW 01 raises a concern with respect to genotoxicity.
- Published
- 2022
- Full Text
- View/download PDF
148. Km4City Ontology Building vs Data Harvesting and Cleaning for Smart-city Services
- Author
-
Bellini, Pierfrancesco, Benigni, Monica, Billero, Riccardo, Nesi, Paolo, and Rauch, Nadia
- Subjects
Computer Science - Databases ,Computer Science - Artificial Intelligence ,Computer Science - Computers and Society - Abstract
Presently, a very large number of public and private data sets are available from local governments. In most cases, they are not semantically interoperable and a huge human effort would be needed to create integrated ontologies and knowledge base for smart city. Smart City ontology is not yet standardized, and a lot of research work is needed to identify models that can easily support the data reconciliation, the management of the complexity, to allow the data reasoning. In this paper, a system for data ingestion and reconciliation of smart cities related aspects as road graph, services available on the roads, traffic sensors etc., is proposed. The system allows managing a big data volume of data coming from a variety of sources considering both static and dynamic data. These data are mapped to a smart-city ontology, called KM4City (Knowledge Model for City), and stored into an RDF-Store where they are available for applications via SPARQL queries to provide new services to the users via specific applications of public administration and enterprises. The paper presents the process adopted to produce the ontology and the big data architecture for the knowledge base feeding on the basis of open and private data, and the mechanisms adopted for the data verification, reconciliation and validation. Some examples about the possible usage of the coherent big data knowledge base produced are also offered and are accessible from the RDF-Store and related services. The article also presented the work performed about reconciliation algorithms and their comparative assessment and selection.
- Published
- 2015
- Full Text
- View/download PDF
149. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital
- Author
-
Annalisa Mondi, Patrizia Lorenzini, Concetta Castilletti, Roberta Gagliardini, Eleonora Lalle, Angela Corpolongo, Maria Beatrice Valli, Fabrizio Taglietti, Stefania Cicalini, Laura Loiacono, Francesco Di Gennaro, Gianpiero D’Offizi, Fabrizio Palmieri, Emanuele Nicastri, Chiara Agrati, Nicola Petrosillo, Giuseppe Ippolito, Francesco Vaia, Enrico Girardi, Maria Rosaria Capobianchi, Andrea Antinori, Sara Zito, Maria Alessandra Abbonizio, Amina Abdeddaim, Elisabetta Agostini, Fabrizio Albarello, Gioia Amadei, Alessandra Amendola, Maria Assunta Antonica, Mario Antonini, Tommaso Ascoli Bartoli, Francesco Baldini, Raffaella Barbaro, Barbara Bartolini, Rita Bellagamba, Martina Benigni, Nazario Bevilacqua, Gianluigi Biava, Michele Bibas, Licia Bordi, Veronica Bordoni, Evangelo Boumis, Marta Branca, Rosanna Buonomo, Donatella Busso, Marta Camici, Paolo Campioni, Flaminia Canichella, Alessandro Capone, Cinzia Caporale, Emanuela Caraffa, Ilaria Caravella, Fabrizio Carletti, Adriana Cataldo, Stefano Cerilli, Carlotta Cerva, Roberta Chiappini, Pierangelo Chinello, Maria Assunta Cianfarani, Carmine Ciaralli, Claudia Cimaglia, Nicola Cinicola, Veronica Ciotti, Francesca Colavita, Massimo Cristofaro, Salvatore Curiale, Alessandra D’Abramo, Cristina Dantimi, Alessia De Angelis, Giada De Angelis, Maria Grazia De Palo, Federico De Zottis, Virginia Di Bari, Rachele Di Lorenzo, Federica Di Stefano, Davide Donno, Francesca Evangelista, Francesca Faraglia, Anna Farina, Federica Ferraro, Lorena Fiorentini, Andrea Frustaci, Matteo Fusetti, Vincenzo Galati, Paola Gallì, Gabriele Garotto, Ilaria Gaviano, Saba Gebremeskel Tekle, Maria Letizia Giancola, Filippo Giansante, Emanuela Giombini, Guido Granata, Maria Cristina Greci, Elisabetta Grilli, Susanna Grisetti, Gina Gualano, Fabio Iacomi, Marta Iaconi, Giuseppina Iannicelli, Carlo Inversi, Maria Elena Lamanna, Simone Lanini, Daniele Lapa, Luciana Lepore, Raffaella Libertone, Raffaella Lionetti, Giuseppina Liuzzi, Andrea Lucia, Franco Lufrani, Manuela Macchione, Gaetano Maffongelli, Alessandra Marani, Luisa Marchioni, Andrea Mariano, Maria Cristina Marini, Micaela Maritti, Annelisa Mastrobattista, Ilaria Mastrorosa, Giulia Matusali, Valentina Mazzotta, Paola Mencarini, Silvia Meschi, Francesco Messina, Sibiana Micarelli, Giulia Mogavero, Marzia Montalbano, Chiara Montaldo, Silvia Mosti, Silvia Murachelli, Maria Musso, Michela Nardi, Assunta Navarra, Martina Nocioni, Pasquale Noto, Roberto Noto, Alessandra Oliva, Ilaria Onnis, Sandrine Ottou, Claudia Palazzolo, Emanuele Pallini, Giulio Palombi, Carlo Pareo, Virgilio Passeri, Federico Pelliccioni, Giovanna Penna, Antonella Petrecchia, Ada Petrone, Elisa Pianura, Carmela Pinnetti, Maria Pisciotta, Pierluca Piselli, Silvia Pittalis, Agostina Pontarelli, Costanza Proietti, Vincenzo Puro, Paolo Migliorisi Ramazzini, Alessia Rianda, Gabriele Rinonapoli, Silvia Rosati, Dorotea Rubino, Martina Rueca, Alberto Ruggeri, Alessandra Sacchi, Alessandro Sampaolesi, Francesco Sanasi, Carmen Santagata, Alessandra Scarabello, Silvana Scarcia, Vincenzo Schininà, Paola Scognamiglio, Laura Scorzolini, Giulia Stazi, Giacomo Strano, Chiara Taibi, Giorgia Taloni, Tetaj Nardi, Roberto Tonnarini, Simone Topino, Martina Tozzi, Francesco Vairo, Alessandra Vergori, Laura Vincenzi, Ubaldo Visco-Comandini, Serena Vita, Pietro Vittozzi, Mauro Zaccarelli, and Antonella Zanetti
- Subjects
Coronavirus ,SARS-CoV-2 ,COVID-19, viral clearance, viral shedding ,Risk factors ,Infectious and parasitic diseases ,RC109-216 - Abstract
Background: Limited data are available about the predictors and outcomes associated with prolonged SARS-CoV-2 RNA shedding (VS). Methods: A retrospective study including COVID-19 patients admitted to an Italian hospital between March 1 and July 1, 2020. Predictors of viral clearance (VC) and prolonged VS from the upper respiratory tract were assessed by Poisson regression and logistic regression analyses. The causal relation between VS and clinical outcomes was evaluated through an inverse probability weighted Cox model. Results: The study included 536 subjects. The median duration of VS from symptoms onset was 18 days. The estimated 30-day probability of VC was 70.2%. Patients with comorbidities, lymphopenia at hospital admission, or moderate/severe respiratory disease had a lower chance of VC. The development of moderate/severe respiratory failure, delayed hospital admission after symptoms onset, baseline comorbidities, or D-dimer >1000 ng/mL at admission independently predicted prolonged VS. The achievement of VC doubled the chance of clinical recovery and reduced the probability of death/mechanical ventilation. Conclusions: Respiratory disease severity, comorbidities, delayed hospital admission and inflammatory markers negatively predicted VC, which resulted to be associated with better clinical outcomes. These findings highlight the importance of prompt hospitalization of symptomatic patients, especially where signs of severity or comorbidities are present.
- Published
- 2021
- Full Text
- View/download PDF
150. Down Syndrome patients with COVID-19 pneumonia: A high-risk category for unfavourable outcome
- Author
-
Serena Vita, Virginia Di Bari, Angela Corpolongo, Delia Goletti, Joaquin Espinosa, Sebastiano Petracca, Fabrizio Palmieri, Emanuele Nicastri, Abbonizio, Chiara Agrati, Fabrizio Albarello, Gioia Amadei, Alessandra Amendola, Mario Antonini, Raffaella Barbaro, Barbara Bartolini, Martina Benigni, Nazario Bevilacqua, Licia Bordi, Veronica Bordoni, Marta Branca, Paolo Campioni, Maria Rosaria Capobianchi, Cinzia Caporale, Ilaria Caravella, Fabrizio Carletti, Concetta Castilletti, Roberta Chiappini, Carmine Ciaralli, Francesca Colavita, Massimo Cristofaro, Salvatore Curiale, Alessandra D’Abramo, Cristina Dantimi, Alessia De Angelis, Giada De Angelis, Rachele Di Lorenzo, Federica Di Stefano, Federica Ferraro, Lorena Fiorentini, Andrea Frustaci, Paola Gallì, Gabriele Garotto, Maria Letizia Giancola, Filippo Giansante, Emanuela Giombini, Maria Cristina Greci, Giuseppe Ippolito, Eleonora Lalle, Simone Lanini, Daniele Lapa, Luciana Lepore, Andrea Lucia, Franco Lufrani, Manuela Macchione, Alessandra Marani, Luisa Marchioni, Andrea Mariano, Maria Cristina Marini, Micaela Maritti, Giulia Matusali, Silvia Meschi, Francesco Messina Chiara Montaldo, Silvia Murachelli, Roberto Noto, Claudia Palazzolo, Emanuele Pallini, Virgilio Passeri, Federico Pelliccioni, Antonella Petrecchia, Ada Petrone, Nicola Petrosillo, Elisa Pianura, Maria Pisciotta, Silvia Pittalis, Costanza Proietti, Vincenzo Puro, Gabriele Rinonapoli, Martina Rueca, Alessandra Sacchi, Francesco Sanasi, Carmen Santagata, Silvana Scarcia, Vincenzo Schininà, Paola Scognamiglio, Laura Scorzolini, Giulia Stazi, Francesco Vaia, Francesco Vairo, and Maria Beatrice Valli
- Subjects
COVID-19 pneumonia ,Down syndrome ,Immune dysregulation ,Immune activation ,Infectious and parasitic diseases ,RC109-216 - Abstract
We report two cases of Corona Virus Disease-19 (COVID-19) in patients with Down Syndrome (DS) and describe the identification, diagnosis, clinical course and management of the infection. Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the upper respiratory tract and higher rate of comorbidities. All these risk factors can contribute to more severe clinical presentations of COVID-19 in this population. It is essential to raise awareness of the clinical relevance of SARS-COV-2 infection in DS patients, as well as in other most vulnerable patients, in order to improve their management and treatment and to encourage vaccinating these individuals early, once a vaccination is available.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.